Table 2.

Asthma Outcomes.^*

Outcome	Acetaminophen (N = 150)	Ibuprofen (N = 150)	Relative Rate (95% CI)	P Value
No. of asthma exacerbations that led to treatment with systemic glucocorticoids: primary outcome — no. of participants (%)†
0	76 (51)	78 (53)	—	—
1	42 (28)	34 (23)	—	—
2	16 (11)	21 (14)	—	—
≥3	16 (11)	15 (10)	—	—
Mean exacerbation frequency over 46 weeks (95% CI)
Among 298 total participants†	0.81 (0.65 to 1.02)	0.87 (0.69 to 1.10)	0.94 (0.69 to 1.28)	0.67
Among 226 participants who completed the trial	0.74 (0.58 to 0.93)	0.70 (0.55 to 0.90)	1.05 (0.75 to 1.45)	0.79
Among 200 participants who completed the trial and used at least one dose of trial medication	0.74 (0.58 to 0.94)	0.77 (0.60 to 1.00)	0.95 (0.68 to 1.32)	0.76
Secondary outcomes
Mean percentage of asthma-control days (95% CI)	85.8 (83.7 to 87.8)	86.8 (84.6 to 88.9)	−1.01 (−3.94 to 1.92)‡	0.50
Mean no. of albuterol rescue inhalations per week (95% CI)	2.8 (2.3 to 3.3)	3.0 (2.4 to 3.6)	−0.2 (−0.9 to 0.6)‡	0.69
Frequency of health care utilization over 46 weeks (95% CI)§	0.75 (0.60 to 0.95)	0.76 (0.60 to 0.97)	0.99 (0.72 to 1.37)	0.94

^*CI denotes confidence interval.

^†Two participants (1%) dropped out of the ibuprofen group during the first 2 weeks without having had an exacerbation and were not included in the primary analysis.

^‡This value is a mean difference (95% CI), rather than a relative rate.

^§Health care utilization included urgent care and emergency department visits and hospitalizations.